A computer implemented method and system are provided. Such a method includes collecting health data from a female subject, assessing hormonal irregularities based on the health data to identify a pattern of hormonal imbalance, and prescribing a personalized herbal formula based on the pattern of hormonal imbalance to prevent or treat a condition or disorder related to a menstrual cycle of the female subject. Health data, which may be collected through online assessment, may include self-reported answers to a list of questions, and one or more photos of tongue of the female subject.

A computer implemented method and system are provided. Such a method includes collecting health data from a female subject, assessing hormonal irregularities based on the health data to identify a pattern of hormonal imbalance, and prescribing a personalized herbal formula based on the pattern of hormonal imbalance to prevent or treat a condition or disorder related to a menstrual cycle of the female subject. Health data, which may be collected through online assessment, may include self-reported answers to a list of questions, and one or more photos of tongue of the female subject.

A computer implemented method and system are provided. Such a method includes collecting health data from a female subject, assessing hormonal irregularities based on the health data to identify a pattern of hormonal imbalance, and prescribing a personalized herbal formula based on the pattern of hormonal imbalance to prevent or treat a condition or disorder related to a menstrual cycle of the female subject. Health data, which may be collected through online assessment, may include self-reported answers to a list of questions, and one or more photos of tongue of the female subject.

The invention provides a method and composition for ameliorating or reducing the symptoms, signs, and markers and for the treatment of irritable bowel syndrome, inflammatory bowel disease or gastritis in a mammal in need thereof, said method comprising administering effective amounts of a pharmaceutically acceptable composition containing at least one probiotic microorganism strain comprising Pediococcus for a time sufficient to ameliorate, reduce or treat at least one symptom, sign, or marker of irritable bowel syndrome, inflammatory bowel disease or gastritis.

The invention provides a method and composition for ameliorating or reducing the symptoms, signs, and markers and for the treatment of irritable bowel syndrome, inflammatory bowel disease or gastritis in a mammal in need thereof, said method comprising administering effective amounts of a pharmaceutically acceptable composition containing at least one probiotic microorganism strain comprising Pediococcus for a time sufficient to ameliorate, reduce or treat at least one symptom, sign, or marker of irritable bowel syndrome, inflammatory bowel disease or gastritis.

A traditional Chinese medicine composition for treating abnormal lung function and laryngitis caused by the influenza virus; the traditional Chinese medicine composition comprising as a primary formula of active ingredients seven medicinal/edible source materials composed of: Siraitia grosvenorii, Cinnamomum cassia, Prunella vulgaris, Houttuynia cordata, Platycodon grandiflorus, Gardenia jasminoides and Glycyrrhiza uralensis. The foundation of the primary formula is supplemented by a secondary formula of seven medicinal/edible source materials consisting of: Citrus reticulata (mandarin orange), Eriobotrya japonica leaves, Angelica dahurica, Arctium lappa root, Piper nigrum, Phragmites australis root and Syzygium aromaticum, and different preparations are prepared. The traditional Chinese medicine combined formula can be a combined formula of source herbs, and can likewise be a combined formula of extracts thereof, and can likewise be a combined formula of source herbs and extracts. The traditional Chinese medicine composition has a significant therapeutic effect on symptoms such as sore throat, itchy throat cough, swelling and pain in the throat, pharyngeal discomfort, etc. resulting from influenza-caused pneumonia such as abnormal lung function and difficulty breathing, cough, lung nodules, ground glass opacity in the lungs, pulmonary fibrosis, interstitial lung disease and laryngitis, and has a certain relieving, progression-stopping and disease condition control and treatment effects on chronic obstructive emphysema.

A traditional Chinese medicine composition for treating abnormal lung function and laryngitis caused by the influenza virus; the traditional Chinese medicine composition comprising as a primary formula of active ingredients seven medicinal/edible source materials composed of: Siraitia grosvenorii, Cinnamomum cassia, Prunella vulgaris, Houttuynia cordata, Platycodon grandiflorus, Gardenia jasminoides and Glycyrrhiza uralensis. The foundation of the primary formula is supplemented by a secondary formula of seven medicinal/edible source materials consisting of: Citrus reticulata (mandarin orange), Eriobotrya japonica leaves, Angelica dahurica, Arctium lappa root, Piper nigrum, Phragmites australis root and Syzygium aromaticum, and different preparations are prepared. The traditional Chinese medicine combined formula can be a combined formula of source herbs, and can likewise be a combined formula of extracts thereof, and can likewise be a combined formula of source herbs and extracts. The traditional Chinese medicine composition has a significant therapeutic effect on symptoms such as sore throat, itchy throat cough, swelling and pain in the throat, pharyngeal discomfort, etc. resulting from influenza-caused pneumonia such as abnormal lung function and difficulty breathing, cough, lung nodules, ground glass opacity in the lungs, pulmonary fibrosis, interstitial lung disease and laryngitis, and has a certain relieving, progression-stopping and disease condition control and treatment effects on chronic obstructive emphysema.

The present disclosure relates to a use of Genipin-1--D-gentiobioside in preparation of a drug, specifically for use in a drug that treats respiratory inflammatory injury caused by coronavirus, respiratory syncytial virus, or Mycoplasma pneumoniae infection. The present disclosure has discovered that Genipin-1--D-gentiobioside possesses the characteristics of reducing viral load, lung index, and inflammatory cytokines in lung tissue following coronavirus infection, respiratory syncytial virus infection, or Mycoplasma pneumoniae infection. It also demonstrates a significant protective effect against death caused by coronavirus infection.

The present disclosure relates to a use of Genipin-1--D-gentiobioside in preparation of a drug, specifically for use in a drug that treats respiratory inflammatory injury caused by coronavirus, respiratory syncytial virus, or Mycoplasma pneumoniae infection. The present disclosure has discovered that Genipin-1--D-gentiobioside possesses the characteristics of reducing viral load, lung index, and inflammatory cytokines in lung tissue following coronavirus infection, respiratory syncytial virus infection, or Mycoplasma pneumoniae infection. It also demonstrates a significant protective effect against death caused by coronavirus infection.

A composition for hormone signaling, blood glucose control, appetite control, and weight management is provided. The composition includes green tea leaf extract, gardenia fructus fruit powder, turmeric root extract, black pepper extract, fenugreek seed extract, ginseng root extract, and white kidney bean extract. A method for hormone signaling, blood glucose control, appetite control, and weight management is provided, comprising administering to the mammal the composition.